Proto Oncogene Tyrosine Protein Kinase Src – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) – Pipeline Review, H1 2020’, provides in depth analysis on Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Respiratory, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology under development targeting Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

– The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Fratagene Therapeutics Srl

Lead Discovery Center GmbH

Onconova Therapeutics Inc

Prous Institute for Biomedical Research SA

TopiVert Ltd

Turning Point Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Overview

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Fratagene Therapeutics Srl

Lead Discovery Center GmbH

Onconova Therapeutics Inc

Prous Institute for Biomedical Research SA

TopiVert Ltd

Turning Point Therapeutics Inc

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Drug Profiles

bosutinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit SRC for Friedreich Ataxia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JRP-890 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nintedanib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ofev – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-150030 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

repotrectinib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Si-306 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SRC for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1288 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1630 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1890 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPX-0022 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPX-0046 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Dormant Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Discontinued Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Jan 13, 2020: Clinical Trial will evaluate Saracatinib in Idiopathic Pulmonary Fibrosis

Nov 28, 2019: Health Canada approves Boehringer’s Ofev to slow SSc-ILD

Nov 19, 2019: New advances in the treatment of advanced lung cancer

Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients

Nov 11, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of TPX-0046, a novel RET/SRC inhibitor

Nov 07, 2019: New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting

Oct 11, 2019: Boehringer’s nintedanib secures breakthrough status in US for ILDs

Oct 10, 2019: FDA grants Ofev breakthrough therapy designation for chronic fibrosing ILDs with a progressive phenotype

Oct 09, 2019: New data showed OFEV (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

Oct 01, 2019: Boehringer Ingelheim announces nintedanib trial met its primary endpoint

Sep 30, 2019: Nintedanib slows progression for broad range of scarring Lung Diseases

Sep 30, 2019: INBUILD meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases

Sep 30, 2019: Turning Point Therapeutics announces FDA clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

Sep 10, 2019: FDA approves Boehringer’s Ofev for rare lung disease

Sep 03, 2019: Turning Point Therapeutics announces updated preclinical Data for TPX-0046, a novel RET/SRC Inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by AbbVie Inc, H1 2020

Pipeline by AstraZeneca Plc, H1 2020

Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Pipeline by Fratagene Therapeutics Srl, H1 2020

Pipeline by Lead Discovery Center GmbH, H1 2020

Pipeline by Onconova Therapeutics Inc, H1 2020

Pipeline by Prous Institute for Biomedical Research SA, H1 2020

Pipeline by TopiVert Ltd, H1 2020

Pipeline by Turning Point Therapeutics Inc, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports